Aurora Ramps Up Medical Cannabis Production In Germany With Enhanced Licenses To Expand Portfolio
Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) has been granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany’s new Medical Cannabis Act (MedCanG).
The company said on Thursday the license grants it continued domestic cultivation, which has been underway for two years now.
Under the new license, the Canadian medical cannabis giant may also cultivate an approved additional product, with plans to expand its offerings to the rapidly growing German patient base.
Additionally, the company said it will also receive a dedicated R&D license, allowing for the trial of up to seven additional novel cultivars at the company’s local EU GMP facility in Leuna, Germany, which has been …